Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

计划入组 343 人 · 首次发布于 2021 年 8 月 3 日

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

计划入组 48 人 · 首次发布于 2023 年 9 月 26 日

Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC

计划入组 28 人 · 首次发布于 2017 年 5 月 2 日

Tivozanib(Fotivda)

C₂₂H₁₉ClN₄O₅ · Rx

Nivolumab(Opdivo, Opdualag, Nivolumab BMS)

Rx

Nivolumab/Relatlimab

Ono Pharmaceutical Co., Ltd.

Japan

Tivozanib Monotherapy Shows Superiority Over Tivozanib Plus Nivolumab in Metastatic RCC After ICI Progression

TiNivo-2 Trial: Nivolumab Fails to Improve Outcomes in Advanced RCC After Prior ICI Therapy

TiNivo-2 Trial Highlights Challenges in ICI Retreatment for Advanced RCC